Adial Pharmaceuticals announces annual shareholder meeting

• Adial Pharmaceuticals will hold its annual stockholder meeting in Charlottesville, Virginia on Sept. 17, 2026.
• Votes include electing two Class II directors to three-year terms ending in 2029, plus ratifying CBIZ CPAs as auditor for 2026.
• Stockholders will vote on large equity issuances tied to the Azora acquisition, including conversion of Series A preferred stock into 12,930,601 common shares.
• Additional approvals cover up to 1,177,782 shares from assumed options, up to 11,780,948 shares from initial pre-funded warrants, plus up to 23,561,896 shares from milestone warrants.
• Ballots also include increasing authorized common shares to 500,000,000, approving 2025 warrant exercises, plus new equity incentive and employee stock purchase plans.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adial Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-093019), on August 24, 2026, and is solely responsible for the information contained therein.